BioRegenx, Inc. (BRGX)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Medical Testing, Diagnostic and Nutraceutical Company	2.34M	3.41M	42.16K	3.99M	7.79M
Medical Testing, Diagnostic and Nutraceutical Company Growth	-31.40%	7991.78%	-98.94%	-48.79%	-
Total	2.34M	3.41M	42.16K	3.99M	7.79M
Total Growth	-31.40%	7991.78%	-98.94%	-48.79%	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
United States	2.34M	3.41M	42.16K	3.99M	7.79M
United States Growth	-31.40%	7991.78%	-98.94%	-48.79%	-
Total	2.34M	3.41M	42.16K	3.99M	7.79M
Total Growth	-31.40%	7991.78%	-98.94%	-48.79%	-

Source: S&P Global Market Intelligence.